Characteristics and Significance of Tertiary Lymphoid Structures Based on Molecular Subtypes in Endometrial Cancer

被引:0
作者
Jia, Hui-Qing [1 ]
Zhang, Shu-Ping [2 ]
Chen, Yang [1 ]
Qiao, Ye-Hua [1 ]
Yao, Yi-Fan [1 ]
Zhang, Xiang-Yan [1 ]
Wu, Si-Yu [3 ]
Song, Yao-Lin [1 ]
Xing, Xiao-Ming [1 ]
机构
[1] Qingdao Univ, Dept Pathol, Affiliated Hosp, 16 Jiangsu Rd, Qingdao 266000, Shandong, Peoples R China
[2] Univ Hlth & Rehabil Sci, Qingdao Hosp, Qingdao Municipal Hosp, Qingdao, Peoples R China
[3] Qingdao Univ, Dept Pathol, Affiliated Yantai Yuhuangding Hosp, Yantai, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Tertiary lymphoid structures; Tumor-infiltrating lymphocytes; Endometrial carcinoma; molecular subtypes; PD-L1; B-CELLS; LYMPHOCYTES; CARCINOMA;
D O I
10.1097/PGP.0000000000001027
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The purpose of this study is to investigate the characteristics and significance of tertiary lymphoid structures (TLSs) in endometrial cancer (EC) based on molecular subtypes. A total of 220 patients with EC were retrospectively enrolled, including 20 with polymerase epsilon ultramutated (POLE-mut), 63 with mismatch repair deficient, 32 with p53 abnormal, and 105 with no specific molecular profile. The presence and maturity of TLSs were determined by immunohistochemical markers (CD3, CD20, CD21, and Bcl6). Disease-free survival served as the endpoint event. TLSs were found in 91 out of 220 patients (41.1%), with 68 located in peritumoral tissues and 37 exhibiting well-formed germinal center structures. The presence and different maturity of TLSs were closely associated with tumor-infiltrating lymphocytes and the programmed cell death ligand-1 expression. Moreover, TLSs displayed heterogeneity across different molecular subtypes. Notably, the TLSs, tumor-infiltrating lymphocytes, and expression of the programmed cell death ligand-1 were significantly enriched in POLE-mut EC. Multivariate logistic regression analysis showed the presence of TLSs (odds ratio: 3.483, 95% CI: 1.044-11.623, P = 0.042) as a potential predictor of POLE-mut EC. Kaplan-Meier survival curves revealed that molecular subtypes significantly stratified prognosis in patients with EC (P = 0.002), whereas TLSs did not. Multivariate Cox regression analysis indicated that The International Federation of Gynecology and Obstetrics stage and Ki-67 expression were independent prognostic factors affecting disease-free survival in patients with EC, and TLSs were not included. In conclusion, TLSs in EC exhibit heterogeneity based on molecular subtypes, necessitating further exploration to determine their clinical application value.
引用
收藏
页码:595 / 604
页数:10
相关论文
共 50 条
  • [41] Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice
    Delvecchio, Francesca R.
    Fincham, Rachel E. A.
    Spear, Sarah
    Clear, Andrew
    Roy-Luzarraga, Marina
    Balkwill, Frances R.
    Gribben, John G.
    Bombardieri, Michele
    Hodivala-Dilke, Kairbaan
    Capasso, Melania
    Kocher, Hemant M.
    [J]. CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2021, 12 (05): : 1543 - 1565
  • [42] Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer
    Koti, Madhuri
    Xu, Amanda Shuo
    Ren, Kevin Yi Mi
    Visram, Kash
    Ren, Runhan
    Berman, David M.
    Siemens, D. Robert
    [J]. BLADDER CANCER, 2017, 3 (04) : 259 - 267
  • [43] The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
    Dijk, Nick van
    Gil-Jimenez, Alberto
    Silina, Karina
    Montfoort, Maurits L. van
    Einerhand, Sarah
    Jonkman, Lars
    Voskuilen, Charlotte S.
    Peters, Dennis
    Sanders, Joyce
    Lubeck, Yoni
    Broeks, Annegien
    Hooijberg, Erik
    Vis, Daniel J.
    Broek, Maries van den
    Wessels, Lodewyk F. A.
    Rhijn, Bas W. G. van
    Heijden, Michiel S. van der
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [44] Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer
    Elfving, Hedvig
    Yu, Hui
    Fessehatsion, Kaleab Kassete
    Brunnstrom, Hans
    Botling, Johan
    Gulyas, Miklos
    Backman, Max
    Lindberg, Amanda
    Strell, Carina
    Micke, Patrick
    [J]. CELLULAR ONCOLOGY, 2025, : 801 - 813
  • [45] Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy
    Fontsa, Mireille Langouo
    Padonou, Francine
    Willard-Gallo, Karen
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (08) : 839 - 847
  • [46] Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer
    Masuda, Tsukasa
    Tanaka, Nobuyuki
    Takamatsu, Kimiharu
    Hakozaki, Kyohei
    Takahashi, Ryohei
    Anno, Tadatsugu
    Kufukihara, Ryohei
    Shojo, Kazunori
    Mikami, Shuji
    Shinojima, Toshiaki
    Kakimi, Kazuhiro
    Tsunoda, Tatsuhiko
    Aimono, Eriko
    Nishihara, Hiroshi
    Mizuno, Ryuichi
    Oya, Mototsugu
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [47] Tertiary lymphoid structures in cancer - considerations for patient prognosis
    Munoz-Erazo, Luis
    Rhodes, Janet L.
    Marion, Valentine C.
    Kemp, Roslyn A.
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (06) : 570 - 575
  • [48] Tertiary Lymphoid Structures in Microorganism-Related Cancer
    Deng, Shuzhe
    Yang, Xinxin
    He, Lin
    Hou, Yunjing
    Meng, Hongxue
    [J]. CANCERS, 2024, 16 (20)
  • [49] Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors
    Ren, Fangping
    Xie, Mei
    Gao, Jie
    Wu, Chongchong
    Xu, Yang
    Zang, Xuelei
    Ma, Xidong
    Deng, Hui
    Song, Jialin
    Huang, Aiben
    Pang, Li
    Qian, Jin
    Yu, Zhaofeng
    Zhuang, Guanglei
    Liu, Sanhong
    Pan, Lei
    Xue, Xinying
    [J]. CANCER MEDICINE, 2022, 11 (15): : 2969 - 2977
  • [50] Treatment options for molecular subtypes of endometrial cancer in 2023
    Karpel, Hannah C. C.
    Slomovitz, Brian
    Coleman, Robert L. L.
    Pothuri, Bhavana
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (03) : 270 - 278